Give us a Call
+6 07 5566445
Send us a Message
iemcjbm@gmail.com
Opening Hours
Everyday: 9AM - 5PM

REFERENCES

1. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Eng J Med 1995;332:329-329.

2. Heart and Stroke Facts: 1996 Statistics Supplement. American Heart Association, Dallas, Tx 1996.

3. Miller M, Seidler , Kwiterovich PO, et al. Long-term predictors of subsequent cardiovascular events with coronay artery disease and “desirable” levels of plasma total cholesterol. Circulation 1992;86:1165-1170.

4. Myerburg RJ, Conde CA, Sung RJ, et al. Clinical electrophysiologic and hemodynamic profile of patients resusitated from prehospital cardiac arrest. Am J Med 1980;68:568-76.

5. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Eng J Med 1984;310:1137-40.

6. Eliot RS, Bratt GT. The paradox of myocardial ischemia and necrosis in young women with normal coronary arteriogram—relationship to anomalous hemoglobin-oxygen dissociation. Am J Cardiol. 1969;23:633-38.

7. Likoff RS, Segal BL, Kasparian H. Paradox of normal selective coronary arteriogram in patients considered to have unmistakable coronary heart disease. N Eng J Med 1967;276:1063.

8. Dear DH, Russel RO, Jones WB et al. Myocardial infarction in the absence of coronary occlusion. Am J cardiol. 1971;28:718.

9. Morris JN. Recent history of coronary disease. Lancet 1951;1:1-7,69-73.

10. Finlayson R. Ischaemic heart disease, aortic aneurysms, and atherosclerosis in the City of London, 1868-1982. Med Hist Suppl 1985;5:151-68.

11. Meade TW, Chakrabarti R. Arterial disease research: Observation or intervention? Lancet 1972;2:913-6.

12. Rose G. Sick individuals and sick populations. Int J Epidemiology 1985;14:32-38.

13. Eaker ED, Packard B, Thom TJ. Epidemiology and risk factors for coronary heart disease in women. Cardiovasc Clin. 1989;19:129-145.

14. Friedman M, Rosenman RH. Association of specific overt behavior pattern with blood and cardiovascular findings. JAMA 1959;169:1286).

15. Friedman MD, Thoresen E, Gill JJ, et al. Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients:summary results of the recurrent coronary prevention project.

16. Mittleman MA, Maclure M. Mental stress during daily life triggers myocardial ischemia. JAMA 1997;277:558-9.

17. Rogers MP,Dubey D, Reich P. The influence of the psyche and the brain on immunity and disease susceptibility. Psychosomatic medicine 1979;41:147-165.

18. Rosenman RH, Brand RJ, Jenkins CD, et al. Coronary artery disease in the Western Collaborative Group Study: final follow-up experience of 8 1/2 years. JAMA 1975;23:872.)

19. Salonen JT, Puska P, Mustaniemi H. Changes in morbidity and mortality during comprehensive community programme to control cardiovascular disease during 1972-79 in North Karelia. BMJ 1979;ii:1178-83.

20. Carruthers ME. Aggression and atheroma. Lancet 1969;2:1170)

21. Blumenthal JA, Williams RB Jr, Kong Y, et al. Type A behavior pattern and coronary atherosclerosis. Circulation 1978;58:634)

22. The Review Panel on Coronary-Prone Behavior and Coronary Artery Disease. A critical review. Circulation 1981;63:1199.)

23. Hammoudeh AJ, Haft JL. Coronary-plaque rupture in acute coronary syndromes triggered by snow shoveling. N Eng J Med 1996;335:2001.

24. Kujala UM. Low LDL oxidation in veterans endurance atheletes. Scandinavian J Medicine Sciene and Sports. 1996;6:303-308.

25. Sue DY, Wasserman K. Impact of integrative cardiopulmonay exercise testing on clinical decision making. Chest 1991;99:981-92.

26. Adner MM, Castelli NP. Elevated high-density lipoprotein levels in marathon runners. JAMA 1980;243:534-6.

27. Weintraub WS, Klein LW, Seelaus PA, et al. Importance of total life consumption of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 1985; 55:660-72.

28. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy exertion: protection against triggering by regular exertion. N Engl J Med 1993;329:1677-1683.

29. Willich SN, Lewis M, Lowell H, et al. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993;329:1684-1690.

30. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH, for the Determinants of Myocardial Infarction Onset Study Investigators. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA 1996;275:1405-1409.

31. Siscovick DS, Weiss NS, Hallstrom AP, Inui TS, Peterson DR. Physical activity and primary cardiac arrest. JAMA 1982;248:3113-3117.

32. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985;6:1233-8.

33. Black A, Black MM, Gensini G. Exertion and acute coronary artery injury. Angiology 1975;26:759-83.

34. Folkers K, Littarru GP, Ho L, et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Inter J Vitamin Nutr Research 1970;4:380-390.

35. Folkers K, Watanabe T, Kaji M. Crtique of coenzyme Q10 in biochemical and biomedical research and in ten years of clinical research in cardiovascular disease. J Mol Med 1977;2:431-460.

36. Nayier WG. The use of coenzyme Q10 to protect ischemic heart muscle. In: Yamamure Y, Folkers K, Ito Y. eds. Biomedical and clinical Aspects of Coenzyme Q. Vol. 2. Amsterdam:Elsevier/North Holland Biochemical Press. 1980:409-425.

37. Ohhara H, Kanaids H, Yoshimura R, et al. Effects of coenzyme Q10 on ischemia and reperfusion of the isolated perfused rat heart. J Mol Cell Cardiol 1981; 13:65-74.

38. Arifa M, Kiyosue T, Imanishi S, et al. Electrophysiologic and ionotropic effects of coenzyme Q10 on gunea pig ventricular muscle. Jpn Heart J 1982;23:961-974.

39. Oharra H, Kanakie H, Nakamura M, et al. A protective effect of coenzyme Q on the adriamycin-induced cardiotoxicity in the isolated perfused rat heart. J Mol Cell Cardiol 1981;13:741-752.

40. Langsjoen H, Langsjoen P, Langsjoen P et al. Usefulness of coenzyme Q10 in clinical cardiology:a long-term study. Mol Aspects Med (England) 1994; 15 Suppl:165-75.

41. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig (Germany). 1993;71(8 Suppl):S116-23.

42. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essemntial hypertension with coenzyme Q10. Mol Aspects Med (England). 1994;15 Suppl:S265-72.

43. McCully KS. Homocysteine metabolism in scurvy, growth and arteriosclerosis. Nature 1971;231:391-392.

44. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The Eurpoean Concerted Action Project. JAMA 1997;277;1775-1781.

45. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-227.

46. McCully KS. Homocystein theory of arteriosclerosis: development and current status. Atheroscler Rev. 1983;11:157-246.

47. Kannel WB. Range of serum cholesterol values in the populaton devloping coronary artery disease. Am J Cardiol 1995;76:69C-77C.

48. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the roll of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.

49. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.

50. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physician. JAMA 1992;268:877-881.

51. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.

52. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-59.

53. Ueland PM, Refsum H, Brattstorm L. Plasma homocysteine and cardiovascular disease. In:Francis RB Jr, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York:Marcel Dekker, 1992:183-236.

54. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smoth cell growth by homocysteine: a link to atherosclerosis. Pro Nat Acad Sci USA 1994;91:6369-73.

55. Stamler JS, Osborne JA, Jaraki O, et al. Adverse effects of homocysteine are modulated by endothelium-derived releasing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.

56. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine B-synthase deficiency. Am J Hum Genet 1985;37:1-31.

57. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl J Med 1997;337:230-236.

58. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.

59. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:877-81; 1992.

60. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-1294.

61. Salonen JT, Nyyssonen K, Korpela H et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish Men. Circulation 1992;86:803-811.

62. Salonen J, Salonen R, Seppanen K, et al. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 1991;302:756-760.

63. Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995;91:645-655.

64. Salonen JT, Alfthan G, Huttunen JK, Pikkarainen J, Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;2:175-179.

65. Kok FJ, Hofman A, Witteman JC, de Bruijn AM, Kruyssen DH, de Bruin M, Valkenburg HA. Decreased selenium levels in acute myocardial infarction. JAMA 1982;261:1161-1164.

66. Salonen JT Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;2:175-9.

67. Virtamo J. Serum selenium and the risk of coronary heart disease and stroke. Am J Epidemiol. 1985;127:276-82.

68. Abram AS, Brooks BA, Eylath U. Chromium and cholesterol-induced atherosclerosis in rabbits. Ann Nutr Metab 1991:35:203-207

69. Schroeder HA, Nason AP, Tipton IH. Chromium deficinecy as a factor in atherosclerosis. J Chronic Dis 1970;23:123-142.

70. Mertz W. Chromium occurrence and function in biological systems. Physiol Rev 1969;49:163-239.

71. Newman HAI, Leighton RF, Lanese RR, et al. Serum chromium and angiographically determined coronary artery disease. Clin Chem 1978;24:541-544.

72. Schroeder HA, Nason AP, Tipton IH. Chromium deficiency as a factor in atherogenesis. J Chronic Dis 1970;23:123-142.

73. Davies S, Howard JM, Hunnisett A, et al. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from

74. Enstrom JE, Kanim LE, Klein MA. Vitamin C Intake and Mortality among a sample of the united States population. Epidemiology 1992;3:194-202.

75. Nyyssonen K, Parvianen MT, Salonen R, et al.Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997;314:634-638.

76. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-386.

77. Stampher MJ, Hennekens CH, Manson JH, et al. Vitamin E consumption and the risk of coronary disease in women. N Eng J Med 1993;328:1444-1449.

78. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992;305:15-19.

Leave a Reply

Your email address will not be published. Required fields are marked *